News

BMJ1d
SAT0576 THE PREVALENCE OF RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW OF POPULATION-BASED STUDIES.
Background: Rheumatoid arthritis (RA) is a heterogeneous disease with unknown aetiology (1). The reported worldwide RA prevalence varies widely (2, 3), and it is unclear whether this is due to ...
BMJ3d
Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus
2 Department of Internal Medicine, General Hospital of Kufstein, Kufstein, Austria 3 Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria 4 Department of Internal ...
BMJ3d
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
22 Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Objectives To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic ...
BMJ3d
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation
Objectives To investigate how individual rheumatoid arthritis (RA) autoantibodies associate with individual signs and symptoms at the time of RA diagnosis. Methods IgA, IgG, IgM rheumatoid factor (RF) ...
BMJ4d
High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
2 Division of Preventive and Behavioral Medicine, University of Massachusetts School of Medicine, Worcester, Massachusetts, USA 3 Division of Clinical Immunology and Rheumatology, University of ...
BMJ4d
Leflunomide: mode of action in the treatment of rheumatoid arthritis
a Academic Ziekenhuis Leiden, Stafcentrum Reumatologie, Leiden, The Netherlands, b Division of Immunology and Allergy, Geneva University Hospital, Geneva, Switzerland Professor F C Breedveld, Academic ...
BMJ4d
EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis
Correspondence to Dr Annette H M van der Helm-van Mil, Department of Rheumatology, Leiden University Medical Center, P.O. Box 9600, Leiden 2300 RC, The Netherlands; AvdHelm{at}lumc.nl Background ...
BMJ4d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ5d
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
Objective To investigate the association between baseline disease activity and the occurrence of flares after adalimumab tapering or withdrawal in patients with rheumatoid arthritis (RA) in sustained ...
BMJ5d
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability ...
Correspondence to Professor Yoshiya Tanaka, First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu 807-8555, Japan; tanaka{at}med.uoeh-u.ac.jp ...
BMJ5d
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled ...
BMJ7d
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
Purpose To evaluate the efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Methods Patients fulfilled Assessment of Spondyloarthritis international ...